I wrote a little bit about this a few weeks ago, when AstraZeneca paused its UK trial of the Oxford vaccine after one subject developed a neurological issue. Sources told the media at the time that the issue in question was transverse myelitis, a disease of the spine. That was the second time AstraZeneca had paused its trial; the first pause, it turned out, was also due to the emergence of a neurological problem in a participant.That issue, it turns out, was Â… transverse myelitis, a condition that normally afflicts one in 236,000 people, per the Times. Two participants...
